Ao jia Yu

Ao jia Yu


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
XCXinxin Chen
Xinxin Chen
XWXiang Wang
Xiang Wang
SWSiyu Wang
Siyu Wang
Xiu-Hang ZhangXiu-Hang Zhang
Xiu-Hang Zhang
AYAo jia Yu
Ao jia Yu
CWCe Wang
Ce Wang

1 December 2016 in Journal of Biomaterials Science, Polymer Edition
Verified
Journal Article
Closed access
XCXinxin Chen
Xinxin Chen
RZRui Zhao
Rui Zhao
XWXiang Wang
Xiang Wang
XLXiang Li
Xiang Li
FPFei Peng
Fei Peng
CWCe Wang
Ce Wang
Wound care treatment is a serious issue faced by the medical staffs due to its variety and complexity. Wound dressings are typically used to manage the various types of wounds. In this study, polyurethane (PU) fibers containing mupirocin (Mu), a commonly used antibiotic in wound care, were fabricated via electrospinning technique. The aim of this study was to develop biomedical electrospun fiber scaffolds for preventing wound infections with good compatibility and to demonstrate their applications as anti-infective burn wound dressings. The surface morphology of fibers was obtained by scanning electron microscopy. FT-IR spectra, water vapor transmission rate, and drug release study in vitro were tested to demonstrate the fiber scaffold characteristic. The prepared PU/Mu composite scaffolds had satisfactory antibacterial activity especially against Staphylococcus aureus. The cell studies revealed that the scaffolds were biocompatible and safe for cell attachment. Histological and immunohistochemical examinations were performed in rats, and the results indicated the histological analysis of tissue stained with H&E showed no obvious inflammation reaction. The results indicated that the electrospun scaffolds were capable of loading and delivering drugs, and could be potentially used as novel antibacterial burn wound dressings.

19 June 2021 in Journal of Food Science
Verified
Journal Article
Closed access
PDF file
YXYan Xue
Yan Xue
XYXiaofeng Yu
Xiaofeng Yu
XZXiuhang Zhang
Xiuhang Zhang
PYPing Yu
Ping Yu
YLYuangeng Li
Yuangeng Li
DSDayun Sui
Dayun Sui

1 February 2020 in Journal of Burn Care & Research
Verified
Journal Article
Closed access
PDF file
Xiu-Hang ZhangXiu-Hang Zhang
Xiu-Hang Zhang
CCChang-Lei Cui
Chang-Lei Cui
HZHao-Yue Zhu
Hao-Yue Zhu
JWJian Wang
Jian Wang
YXYan Xue
Yan Xue
XCXin-Xin Chen
Xin-Xin Chen
The aim of the study was to investigate the effects of the rhGM-CSF gel on third degree frostbite wounds. 62 patients who had suffered third degree frostbite on their hand or foot (91 wounds in total ) were selected using a convenience sampling method and randomly allocated to two groups: the rhGM-CSF group(31patients,45 frostbite wounds) received the rhGM-CSF gel when wound dressing change daily, however, the control group (31patients, 46 frostbite wounds) received aloe glue. The wound healing time , the score of inflammation about the wound and the positive bacterial culture of wound secretions was used to measure outcomes respectively. Data were analyzed using SPSS (25.0), student's t test or Mann-Whitney U test and Chi-square test or Fisher exact test were selected, as appropriate. The healing time of the rhGM-CSF group was (12.2±5.0) days, which was significantly shorter than that of the control group (15.5±4.7) days (P <0.0001). The rhGM-CSF group's wound inflammation scores on the 7th and 14th day of treatment were (0.96±0.21) and (1.88±0.29) respectively, which were better than those of the control group (1.12±0.24) and (1.38±0.15) (both P <0.0001). The positive bacterial culture of wound secretions in the rhGM-CSF group was also better than that in the control group on the 3rd , 7th and 14th day after treatment (P =0.027, 0.004, 0.030 respectively). According to the results, using rhGM-CSF gel considerably increases the speed of frostbite wounds healing, and have an effect on protecting third degree frostbite wounds regarding the positive effects.


25 May 2026 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
XCXin xin Chen
Xin xin Chen
ZYZhe Yin
Zhe Yin
XZXiu-Hang Zhang
Xiu-Hang Zhang
JHJie Hao
Jie Hao
QZQi Zhou
Qi Zhou
JWJun Wu
Jun Wu
Background: Spinal cord injury (SCI) causes irreversible neurological deficits and represents a major global health and socioeconomic burden. Although neural progenitor cell (NPC) transplantation is strongly supported by preclinical evidence through cell replacement, intrinsic neuroregeneration, and broad neurotrophic and immunomodulatory effects, its clinical translation has progressed more slowly than anticipated. In parallel, rapid advances in gene editing, biomaterial engineering, and organoid technologies are reshaping the therapeutic landscape. Therefore, it is timely to systematically re-evaluate the current evidence on NPC-based therapies for SCI and to refine future translational strategies. Main body: This review provides an updated and comprehensive overview of NPC therapy for SCI across the full translational continuum. First, we summarize the biological properties, advantages, and limitations of NPCs derived from adult or embryonic neural tissues, embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs), highlighting issues such as tumorigenicity, immune responses, and manufacturing standardization. We then focus on efficacy-oriented genetic modifications and engineered delivery systems, including NPCs overexpressing neurotrophic, synaptogenic, or pro-survival factors, as well as combination strategies integrating NPCs with biomaterials, small molecules, or immunomodulatory agents to enhance graft survival, circuit reconstruction, and motor and sensory recovery. Subsequently, we systematically analyze 19 clinical trials of NPC/NSC-based products conducted in 10 countries, covering HuCNS-SC, LCTOPC1, NSI-566, hESC-OPC, and the emerging iPSC-derived product XS228. Trial designs, dosing regimens, routes of administration, safety profiles, and preliminary functional outcomes are compared, and key design principles for next-generation clinical trials and patient selection are proposed. Finally, we discuss organoid-based approaches and artificial intelligence (AI)–assisted decision tools as emerging platforms for disease modeling, protocol optimization, and precision indication refinement. Conclusion: NPC-based therapy for SCI remains at an early but promising translational stage. No NPC product has yet achieved regulatory approval, reflecting persistent challenges in cell source optimization, safety control, graft survival, in vivo tracking, and trial design. Nevertheless, by integrating rigorous cell source selection, rational gene modification, advanced delivery systems, and well-designed clinical trials targeting carefully defined patient populations, NPCs are expected to achieve meaningful—and potentially transformative—clinical benefits for individuals with SCI in the future.